Loading stock data…
PRCT
$28.78+0.43 (+1.52%)
After Hours$28.99+0.21 (+0.73%)· Last close Jun 9
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
PROCEPT BioRobotics Corporation in the Healthcare sector is trading at $28.78 with a market capitalization of $1.5B. Wall Street consensus targets $30.44 (9 analysts), implying a +5.8% move over the next 12 months. The stock is currently 56% below its 52-week high of $64.92, remaining 5.9% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +5.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$28.78
Potential Downside
0%
Whystock Fair Value$28.78
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus9 analysts
Buy
Mean target$30.44+5.8%
Range$20.00 – $37.00
Fundamentals
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic syste...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.50B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.83
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-29.47%
Volume
Today's trading volume
1.29M
Recent News
PROCEPT BioRobotics (PRCT) Is Down 9.2% After Aquablation WATER IV Milestones - What's Changed
PROCEPT BioRobotics recently reported two major milestones in its WATER IV prostate cancer program, completing enrollment in the randomized WATER IV RP trial comparing Aquablation therapy with radical prostatectomy and securing FDA IDE approval for a second randomized study against active surveillance. These twin trials position Aquablation as a potential alternative to both surgery and watchful waiting in prostate cancer care, with ten-year follow-up planned to assess long-term disease...
Here’s What the Street Thinks About PROCEPT BioRobotics Corporation (PRCT)
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is one of the best robotic surgery stocks to buy. PROCEPT BioRobotics Corporation (NASDAQ:PRCT) received several rating updates following the release of its financial results for fiscal Q1. Piper Sandler lifted the price target on PROCEPT BioRobotics Corporation (NASDAQ:PRCT) to $35 from $28 on April 30, maintaining an Overweight rating on the […]
This Healthcare Investor Added $43 Million to a Genomics Leader Growing Volume 34%
GeneDx Holdings delivers AI-powered clinical and genomic data analysis for healthcare providers seeking precision medicine solutions.
5 Robotics Stocks to Watch as Physical AI Builds Momentum
As AI moves from the digital world into the physical one, robotics stocks are emerging as one of the market's most compelling early-stage opportunities.
Q1 Results Say a Lot About Procept Biorobotics Corp (PRCT) Stock Outlook
Procept Biorobotics Corp (NASDAQ:PRCT) is one of the best small cap robotics stocks to buy according to analysts. The Street expects PRCT stock to pop 47% from its current level. Procept Biorobotics Corp (NASDAQ:PRCT) released its Q1 2026 report on April 29. It delivered revenue of $83.1 million, which rose 20% YoY and surpassed analysts’ […]